One of the biggest challenges is several conditions present with overlapping symptoms including:
By improving the patient experience through our novel Cardiac Analysis Platform
Announcing FDA Clearance
One of the biggest challenges is several conditions present with overlapping symptoms including:
To detect each of these requires separate and distinct tests and appointments.
The Impact
To date, there has not been a detection platform available which can distinguish or identify which of these conditions may be the culprit for the symptoms.
Point-of-care, no specialist training required
Multiple conditions at once*
Non-additive to healthcare costs
Scalable platform
Adaptable for various settings; rural and underserved
The CorVista® System with coronary artery disease (CAD) Add-On has the ability within minutes to non-invasively indicate the likelihood of significant CAD at the point-of-care as an aid in diagnosis.
Once approved, the CorVista System will have the ability to predict the presence of other cardiac conditions such as Left Ventricular Filling Pressure and Pulmonary Hypertension.
Evaluates cardiovascular anomalies without radiation or the typical patient burden of traditional stress testing
Delivers predictive assessments on cardiovascular disease
Allows for patient procedure and consultation with physician, who will have report available at her or his fingertips, in a single visit
Enables rapid diagnosis, connecting patients to appropriate treatments more quickly
Collects patient signals on simple, digital device
Uses powerful machine-learned algorithms to generate analyses, all run on the cloud
The CorVista System has the potential to change the way cardiovascular disease is diagnosed by providing patients and physicians with valuable insights in a single visit.
Signals naturally emitted by the heart are collected while the patient is at rest and are automatically transferred to cloud.
Complex mathematical calculations are performed on patient data, and proprietary machine-learned algorithms generate results on the presence of cardiovascular disease.
CorVista® Analysis is available to physicians in a secure, web portal shortly after the procedure is completed.
“The CorVista® System with CAD add-on has been cleared to market as a 510(k) device. Please contact [email protected] for more information.“
“CAUTION – Additional CorVista System Add-ons for Pulmonary Hypertension and LV Filling Pressure are currently investigational devices limited by federal law (or United States) law to investigational use and are not available for commercial distribution.”
